Immune Cell-Based Clustering Reveals Clinically Distinct Endotypes in Type 2 Diabetes
Authors:
- Nicolas VenteclefNVNicolas Venteclef
- Jacqueline Ratter-RieckJRJacqueline Ratter-Rieck
- Jeanbaptiste JullaJJJeanbaptiste Julla
- Marc DiedisheimMDMarc Diedisheim
- Violeta RaverdyVRVioleta Raverdy
- Matthias HepprichMHMatthias Hepprich
Preprint
- 8 October 2025
- preprint
- Published by Springer Nature in Research Square
Abstract
Type 2 diabetes (T2D) is a heterogeneous disease, yet current classifications fail to capture its complexity or enable precision care. Here, we introduce a clinically scalable, immune-based endotyping strategy using routine blood immune cell counts - neutrophils, lymphocytes, and monocytes - from over 1,500 individuals with newly diagnosed T2D across three independent longitudinal European cohorts. Unsupervised clustering identified four consistent and clinically meaningful immune endotypes: Severe Inflammatory Diabetes (SIND), Mild Inflammatory Diabetes (MIND), Lymphocyte-Rich Diabetes (LYRD), and Lymphocyte-Deficient Diabetes (LYDD), that named immunotypes. These endotypes were associated with divergent long-term outcomes, with SIND and LYDD showing increased cardiovascular, renal, and mortality risks, and MIND and LYRD linked to more favorable trajectories. Multi-omic profiling revealed endotype-specific inflammatory signatures, including selective expansion of CCR2hi and CD39hi classical monocytes in the SIND endotype. Integration with single-cell RNA-seq uncovered distinct monocyte subsets in SIND, enriched for chemotaxis and myeloid activation transcriptional programs, alongside skewed adaptive immunity. Strikingly, this pro-inflammatory immune profile was attenuated by IL-1β antagonism and bariatric surgery-induced diabetes remission, underscoring its therapeutic relevance. These findings position immune-based endotyping as a robust and accessible tool to stratify risk, uncover disease mechanisms, and guide personalized intervention strategies in T2D.Keywords
All Related Versions
This publication has 48 references indexed in Scilit:
- Recognising, quantifying and accounting for classification uncertainty in type 2 diabetes subtypesDiabetologia, 2025
- A novel subpopulation of monocytes with a strong interferon signature indicated by SIGLEC-1 is present in patients with in recent-onset type 1 diabetesDiabetologia, 2024
- High-throughput genetic clustering of type 2 diabetes loci reveals heterogeneous mechanistic pathways of metabolic diseaseDiabetologia, 2022
- A novel diabetes typology: towards precision diabetology from pathogenesis to treatmentDiabetologia, 2022
- Long-Term Improvement of Chronic Low-Grade Inflammation After Bariatric SurgeryObesity Surgery, 2021
- Impact of bariatric surgery on type 2 diabetes: contribution of inflammation and gut microbiome?Seminars in Immunopathology, 2019
- LIGHT/TNFSF14 is increased in patients with type 2 diabetes mellitus and promotes islet cell dysfunction and endothelial cell inflammation in vitroDiabetologia, 2016
- Effect of bariatric surgery on systemic and adipose tissue inflammationSurgical Endoscopy, 2015
- Association of Bariatric Surgery With Long-term Remission of Type 2 Diabetes and With Microvascular and Macrovascular ComplicationsJAMA, 2014
- Contribution of monocytes Siglec-1 in stimulating T cells proliferation and activation in atherosclerosisAtherosclerosis, 2012